One-Shot gene therapy could free hemophilia b patients from frequent injections
Disease control
Ongoing
This clinical trial is testing a one-time gene therapy called BBM-H901 for people with hemophilia B, a bleeding disorder caused by low levels of clotting factor IX. The therapy uses a harmless virus to deliver a working copy of the factor IX gene to the liver, so the body can pro…
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Xinzhi BioMed Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC